Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was 23,472 pound [range: 1,411- pound 90,262] pound, split between drug costs 11,191 pound and other resource use costs 12,281 pound. The cost per assumed quality-adjusted life year (QALY) during DRMM was 66,983 pound. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.